Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
Department of Health and Human Services
Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.
Funding
Award size
Not specified
Type
Grant
Dates
Deadline
Later
Posted
11/04/2024
Closes
2027-10-20
Eligibility
Eligibility
Small businessesNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationNative American tribal organizations (other than Federally recognized tribal governments)Independent school districtsState governmentsPrivate institutions of higher educationFor profit organizations other than small businessesNonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationCity or township governmentsCounty governmentsPublic housing authorities/Indian housing authoritiesSpecial district governmentsOthers (see text field entitled "Additional Information on Eligibility" for clarification)Public and State controlled institutions of higher educationNative American tribal governments (Federally recognized)
Program
Funding area
Health - HL
Opportunity #
PAR-25-225
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov